CLINICAL TRIALS PROFILE FOR TRETTEN

All Clinical Trials for TRETTEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01862367 ↗	Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study	Completed	Novo Nordisk A/S		2013-05-17	This study is conducted globally. The aim of this observational study is to investigate the incidence of specific adverse drug reactions associated with the use of recombinant factor XIII (NovoThirteen®) in patients with congenital FXIII A-subunit deficiency (congenital FXIII deficiency), comprising FXIII antibodies, allergic reactions, embolic and thrombotic events and lack of therapeutic effect. The study will aim at observing all patients exposed to NovoThirteen® in the EU, and additional patients from selected non-EU countries. Recombinant FXIII (rFXIII) is registered in EU and Switzerland as NovoThirteen® and in Canada as Tretten®.

Clinical Trial Conditions for TRETTEN

Condition Name

Condition Name for TRETTEN
Intervention	Trials
Congenital Bleeding Disorder	1
Congenital FXIII Deficiency	1

Condition MeSH

Condition MeSH for TRETTEN
Intervention	Trials
Blood Coagulation Disorders	1
Hemostatic Disorders	1

Clinical Trial Locations for TRETTEN

Trials by Country

Trials by Country for TRETTEN
Location	Trials
United States	6
Canada	2
Denmark	1
Spain	1
Italy	1

Trials by US State

Trials by US State for TRETTEN
Location	Trials
Michigan	1
Georgia	1
Florida	1
California	1
Ohio	1

Clinical Trial Progress for TRETTEN

Clinical Trial Phase

Clinical Trial Phase for TRETTEN
Clinical Trial Phase	Trials

Clinical Trial Status

Clinical Trial Status for TRETTEN
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for TRETTEN

Sponsor Name

Sponsor Name for TRETTEN
Sponsor	Trials
Novo Nordisk A/S	1

Sponsor Type

Sponsor Type for TRETTEN
Sponsor	Trials
Industry	1